The company might have blown Enliven out of the water.

Tecvayli plus Darzalex could challenge Carvykti in the push for a functional cure.

Pfizer reveals the discontinuation of PF-08046044.

Linker-MM4 data raise more questions about sequencing of therapies for multiple myeloma.

It’s less about being fast, more about producing a better product.

The first stage of Preserve-003 shows a survival benefit in post-PD-(L)1 lung cancer – with caveats.

Of 15 treatment-emergent adverse events, only one was deemed related to therapy.